| Bristol Myers Squibb Co.announced 26 Oct 2023 |
Initiate Phase 3 trial for Krazati plus pembrolizumab due after leader left |
No record found31 Dec 2023 |
| Bristol Myers Squibb Co.announced 26 Oct 2023 |
Submit Phase 2 data for 3L+ CRC due after leader left |
No record found31 Dec 2023 |
| Bristol Myers Squibb Co.announced 26 Oct 2023 |
Close the acquisition of Mirati Therapeutics due after leader left |
No record found30 Jun 2024 |
| Bristol Myers Squibb Co.announced 26 Oct 2023 |
Report Phase 2 data for Krazati plus pembrolizumab and chemotherapy due after leader left |
No record found30 Jun 2024 |
| Bristol Myers Squibb Co.announced 26 Oct 2023 |
Initiate Phase 2 trial for selective PRMT5/MTA inhibitor due after leader left |
No record found30 Jun 2024 |
| Bristol Myers Squibb Co.announced 26 Oct 2023 |
Report Phase 3 data for Krazati plus cetuximab due after leader left |
Not met31 Dec 2024 |
| Bristol Myers Squibb Co.announced 27 Apr 2023 |
Close the acquisition of a vector facility due after leader left |
No record found31 Dec 2023 |
| Bristol Myers Squibb Co.announced 9 Jan 2023 |
Initiate Atrial Fibrillation and Acute Coronary Syndrome trials for milvexian |
No record found30 Jun 2023 |
| Bristol Myers Squibb Co.announced 9 Jan 2023 |
Initiate post-transplant maintenance trial for iberdomide in multiple myeloma due after leader left |
Met31 Dec 2023 |
| Bristol Myers Squibb Co.announced 4 Feb 2022 |
Launch relatlimab plus nivolumab, mavacamten, and deucravacitinib |
Met31 Dec 2022 |
| Bristol Myers Squibb Co.announced 16 Nov 2021 |
Launch mavacamten |
Met31 Dec 2022 |
| Bristol Myers Squibb Co.announced 16 Nov 2021 |
Complete Phase 1 for five assets due after leader left |
No record found31 Dec 2023 |
| Bristol Myers Squibb Co.announced 11 Jan 2021 |
Submit U.S. application for Mavacamten for obstructive HCM |
Met31 Mar 2021 |
| Bristol Myers Squibb Co.announced 11 Jan 2021 |
Initiate Phase 3 trial for Myelofibrosis |
No record found31 Mar 2021 |
| Bristol Myers Squibb Co.announced 11 Jan 2021 |
Initiate Phase 3 trial for PsA |
No record found31 Dec 2021 |
| Bristol Myers Squibb Co.announced 11 Jan 2021 |
Report ORR data for CELMoD agents |
Met31 Dec 2021 |
| Bristol Myers Squibb Co.announced 11 Jan 2021 |
Initiate clinical trials for earlier lines of multiple myeloma |
No record found31 Dec 2021 |
| Bristol Myers Squibb Co.announced 11 Jan 2021 |
Report Phase 2 proof-of-concept data for IBD or lupus |
No record found31 Dec 2021 |
| Bristol Myers Squibb Co.announced 11 Jan 2021 |
Launch Liso-cel for 2L TE & TNE DLBCL |
No record found31 Dec 2021 |
| Bristol Myers Squibb Co.announced 11 Jan 2021 |
Report Phase 2 proof-of-concept data for Factor XIa inhibitor |
Met31 Dec 2022 |
| Bristol Myers Squibb Co.announced 13 Nov 2020 |
Close the acquisition of MyoKardia, Inc |
Met31 Dec 2020 |
| Bristol Myers Squibb Co.announced 5 Oct 2020 |
Submit a New Drug Application for mavacamten to the FDA |
Met31 Mar 2021 |
| Bristol Myers Squibb Co.announced 26 Aug 2019 |
Close the pending merger with Celgene |
Met31 Dec 2019 |
| Bristol Myers Squibb Co.announced 2 May 2019 |
Expire the Exchange Offers |
Not met3 Jun 2019 |
| Bristol Myers Squibb Co.announced 2 May 2019 |
Close the acquisition of Celgene |
Late30 Sep 2019 |
| Bristol Myers Squibb Co.announced 8 Mar 2019 |
Complete the acquisition of Celgene Corporation |
Late30 Sep 2019 |
| Bristol Myers Squibb Co.announced 19 Dec 2018 |
Complete the sale of the UPSA consumer health business |
Late30 Jun 2019 |
| Bristol Myers Squibb Co.announced 14 Feb 2018 |
Complete the strategic development and commercialization collaboration with Nektar Therapeutics |
Met30 Jun 2018 |
| Bristol Myers Squibb Co.announced 14 Feb 2018 |
Initiate pivotal studies in renal cell carcinoma and melanoma |
Met30 Jun 2018 |
| Bristol Myers Squibb Co.announced 14 Feb 2018 |
Initiate registration-enabling studies in the joint clinical development plan |
No record found14 Apr 2019 |
| Bristol Myers Squibb Co.announced 27 Jul 2017 |
Complete the sale of manufacturing operations in Swords, Ireland to SK Biotek |
Met31 Dec 2017 |